{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:48:43Z","timestamp":1782139723420,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2023.1276396","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:21:41Z","timestamp":1700814101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Leveraging stories of cardiac amyloidosis patients of African ancestry or descent to support patient-derived data elements for efficient diagnosis and treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Rachele M.","family":"Hendricks-Sturrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B2","unstructured":"(Primary) amyloidosis2022"},{"key":"B3","unstructured":"Beyond imagination | amyloidosis foundation\n            BaxtonE.II\n          2022"},{"key":"B4","unstructured":"Cece\u2019s story, amyloidosis research consortium\n            BeckwithC.\n            HereditaryATTR\n          2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"B6","unstructured":"\u2018Tafamidis prior authorization with quantity limit program summary\u2019. Copyright prime therapeutics LLC2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107238","DOI":"10.1016\/j.cct.2023.107238","article-title":"Equity and bias in electronic health records data","volume":"130","author":"Boyd","year":"2023","journal-title":"Contemp. Clin. Trials"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jamia\/ocad115","article-title":"Potential bias and lack of generalizability in electronic health record data: reflections on health equity from the National Institutes of Health Pragmatic Trials Collaboratory","volume":"30","author":"Boyd","year":"2023","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B9","unstructured":"NBA legend discusses rare heart disease that mostly affects african Americans | BlackPressUSA\n            BrownS. M.\n          2022"},{"key":"B10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"107171","DOI":"10.1016\/j.cct.2023.107171","article-title":"Implementation and evaluation of an expanded electronic health record-integrated bilingual electronic symptom management program across a multi-site Comprehensive Cancer Center: the NU IMPACT protocol","volume":"128","author":"Cella","year":"2023","journal-title":"Contemp. Clin. Trials"},{"key":"B12","unstructured":"\u2018Table of pharmacogenomic biomarkers in Drug labeling\u2019, FDA2023"},{"key":"B13","unstructured":"ICD-10-CM official guidelines for coding and reporting FY 20232023"},{"key":"B14","unstructured":"USING Z CODES: the social determinants of health (SDOH) data journey to better outcomes2023"},{"key":"B15","unstructured":"Cigna national formulary coverage policy: PA amyloidosis \u2013 tafamidis products2023"},{"key":"B16","unstructured":"All in and NADPH (2022) \u2018people with lived experiences of inequity in data sharing projects"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s11136-023-03354-9","article-title":"A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis","volume":"32","author":"D\u2019Souza","year":"2023","journal-title":"Qual. Life Res."},{"key":"B18","unstructured":"Cardiac amyloid \u2013 an update\n            DunguJ. N.\n          2015"},{"key":"B19","article-title":"The future of healthcare requires a direct connection to patients to better understand their lived experiences","year":"","journal-title":"STAT"},{"key":"B20","unstructured":"Leading causes of death2023"},{"key":"B21","unstructured":"Amyloidosis: greg\u2019s story, amyloidosis research consortium\n            FosterG."},{"key":"B22","unstructured":"Genetic origins, diagnosis and treatment of hereditary amyloidosis on african Americans2022"},{"key":"B23","unstructured":"Geographic origins, diagnosis and treatment of hereditary amyloidosis - african Americans2023"},{"key":"B24","unstructured":"Overview of amyloidosis - UpToDate\n            GorevicP.\n          2023"},{"key":"B25","unstructured":"Engendering equity in biomedical research by meeting communities where they are - bill of health\n            Hendricks-SturrupR.\n          2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/amajethics.2021.240","article-title":"African American Nurses\u2019 perspectives on genomic medicine research","volume":"23","author":"Hendricks-Sturrup","year":"2021","journal-title":"AMA J. Ethics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/jpm11090850","article-title":"Patient-reported outcomes following genetic testing for familial hypercholesterolemia, breast and ovarian cancer syndrome, and lynch syndrome: a systematic review","volume":"11","author":"Hendricks-Sturrup","year":"2021","journal-title":"J. Personalized Med."},{"key":"B28","unstructured":"Amyloidosis diagnosis | amyloidosis foundation\n            Jackson-WebbA.\n          2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/mgg3.231","article-title":"The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa","volume":"4","author":"Jacobson","year":"2016","journal-title":"Mol. Genet. Genomic Med."},{"key":"B30","unstructured":"Transthyretin amyloid cardiomyopathy (ATTR-CM)\u2019, in StatPearls. Treasure island (FL): StatPearls publishing\n            JainA.\n            ZahraF.\n          2023"},{"key":"B31","unstructured":"Multiple myeloma awareness and african American disparities - NCI\n            KumarS.\n            LittleR.\n            DavisC.\n          2017"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3122\/jabfm.2016.01.150141","article-title":"Stakeholder engagement in a patient-reported outcomes (PRO) measure implementation: a report from the SAFTINet practice-based research network (pbrn)","volume":"29","author":"Kwan","year":"2016","journal-title":"J. Am. Board Fam. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0128","DOI":"10.1097\/MD9.0000000000000128","article-title":"Multiple myeloma-associated light chain amyloidosis involving heart, kidneys, and peripheral nerves: a case report","volume":"2","author":"Lee","year":"2021","journal-title":"Med. Case Rep. Study Protoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11795468211015230","DOI":"10.1177\/11795468211015230","article-title":"Best practices in specialized amyloidosis centers in the United States: a survey of cardiologists, Nurses, patients, and patient advocates","volume":"15","author":"Nativi-Nicolau","year":"2021","journal-title":"Clin. Med. Insights Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"B36","first-page":"32","volume-title":"National Black Nurses association news","year":"2019"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"ATTR Epidemiol. Genet. Prognostic Factors"},{"key":"B38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/PROM.S411721","article-title":"The transthyretin amyloidosis \u2013 quality of life (ATTR-QOL) Questionnaire: development of a conceptual model and disease-specific patient-reported outcome measure\u2019","volume":"14","author":"O\u2019Connor","year":"2023","journal-title":"Patient Relat. Outcome Meas."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B40","unstructured":"RCSB PDB - 4TLT: crystal structure of human transthyretin\n            SaelicesL.\n            CascioD.\n          2015"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28932","DOI":"10.1074\/jbc.M115.659912","article-title":"Uncovering the mechanism of aggregation of human transthyretin","volume":"290","author":"Saelices","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B42","unstructured":"Life is what you make it | amyloidosis foundation\n            StricklandL. (n.d."},{"key":"B43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.rdc.2021.08.004","article-title":"Using the electronic health record to enhance care in pediatric rheumatology","volume":"48","author":"Taxter","year":"2022","journal-title":"Rheum. Dis. Clin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.cardfail.2020.09.384","article-title":"Impact of tafamidis on life expectancy and quality of life of transthyretin amyloid cardiomyopathy patients","volume":"26","author":"Tran","year":"2020","journal-title":"J. Cardiac Fail."},{"key":"B45","unstructured":"Vyndamax (tafamidis) - prior authorization\/medical necessity -2023"},{"key":"B46","unstructured":"Current and potential therapeutic strategies for transthyretin cardiac amyloidosis\u2019, Frontiers in Drug Discovery\n            WilliamsM. A. C.\n          2022"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1276396\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:21:50Z","timestamp":1700814110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1276396\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":46,"alternative-id":["10.3389\/fphar.2023.1276396"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1276396","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"article-number":"1276396"}}